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Activated protein C (APC) is a serine protease with
anticoagulant, anti-inflammatory, and cytoprotective
properties. Using recombinant APC, we identified
a class of single-stranded DNA aptamers (HS02)
that selectively bind to APC with high affinity. Interac-
tion of HS02 with APC modulates the protease
activity in a way such that the anticoagulant functions
of APC are inhibited and its reactivity toward the
protein C inhibitor is augmented in a glysoaminogly-
can-like fashion, whereas APC’s antiapoptotic and
cytoprotective functions remain unaffected. Based
on these data, the binding site of HS02 was localized
to the basic exosite of APC. These characteristics
render the exosite-specific aptamers a promising
tool for the development of APC assays and a poten-
tial therapeutic agent applicable for the selective
control of APC’s anticoagulant activity.
INTRODUCTION
The blood clotting process is a series of enzymatic reactions
leading to the final formation of thrombin (Mann et al., 2003).
To avoid overcoagulation with the risk of thrombus formation,
this process is controlled by several anticoagulant mechanisms,
such as the heparin-antithrombin pathway and the protein
C- pathway (Dahlba¨ck and Villoutreix, 2005). The key enzyme
of the protein C pathway is activated protein C (APC), a serine
protease that is generated from its zymogen protein C (PC)
(Esmon, 2003; Griffin et al., 2007). Formation of APC is a two-
step process that occurs on the surface of endothelial cells in
a thrombin-dependent manner (Griffin et al., 2007). It requires
binding of PC to the endothelial cell PC receptor (EPCR), fol-
lowed by proteolytic activation of PC through thrombin/throm-
bomodulin complexes (Esmon, 2003).
Once activated and dissociated from EPCR, APC regulates
further thrombin formation by cleavage of its two main
substrates, the activated cofactors V (FVa) and VIII (FVIIIa)
(Dahlba¨ck and Villoutreix, 2005). In addition to its anticoagulant442 Chemistry & Biology 16, 442–451, April 24, 2009 ª2009 Elsevierfunctions, APC shows cytoprotective effects, including anti-
inflammatory and antiapoptotic activities, and protection of
endothelial barrier function (Griffin et al., 2007). These direct
effects of APC on cells require EPCR and the G protein-coupled
receptor, protease activated receptor-1 (PAR-1) (Vu et al., 1991;
Riewald et al., 2002).
The activity of the PC pathway is controlled by the rate of PC
activation and APC inactivation. The major APC inactivator in
human plasma is the protein C inhibitor (PCI), a member of the
serpin superfamily (Huntington and Li, 2009). As found for other
serpins, such as antithrombin and heparin cofactor II, addition of
the glycosaminoglycan heparin augments the inactivation
kinetics of APC by PCI (Aznar et al., 1996).
These multiple functions of APC require interactions with
various plasmatic and cellular proteins. These molecular interac-
tions are controlled and directed through amino acid sequences
on APC’s surface that are remote from the active site and termed
exosites. Basic residues on three surface loops of APC, the
37-loop, the 60-loop, and the 70–80-loop, form a basic exosite
that is involved in inactivation of factors Va and VIIIa (Dahlba¨ck
and Villoutreix, 2005; Griffin et al., 2007). A second exosite
formed by acidic residues of the 162 helix is located on the left
side of the active site toward the back of the molecule and deter-
mines the specificity of APC in the interaction with PAR-1
(Figure 1A) (Yang et al., 2007).
The importance of the PC anticoagulant pathway is demon-
strated by the life-long thrombotic tendency of patients showing
inherited deficiencies of PC or other dysfunctions of the PC
pathway as APC resistance (Dahlba¨ck and Villoutreix, 2005).
Moreover, acquired PC deficiency contributes to the develop-
ment of microvascular thrombosis in septicemia. Consequently,
substitution with recombinant APC reduces mortality rates in
severe sepsis (Bernard et al., 2001). A severe side effect of
APC substitution, however, is major bleeding that occurs in
2% of patients (Levi, 2008). This severe side effect limits its clin-
ical use. An APC-specific antidote would be helpful to manage
APC-induced bleeding.
In addition, blockade of APC’s anticoagulant activity might
be an adjuvant approach for hemophilia treatment. Evidence
that inhibition of APC might partially compensate for the absence
of FVIII comes from in vitro studies with peptidomimetic or ben-
zamidine-based APC inhibitors (Butenas et al., 2006; De NanteuilLtd All rights reserved
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against thrombin, which might limit their therapeutic efficacy.
This and the unknown toxicity of both substances emphasize
the need for a nontoxic and highly specific APC inhibitor. In addi-
tion, a ligand that binds APC with high affinity but shows selec-
tivity against the proenzyme PC can be used as a selective
detector of APC and allows for the development of a test system
for determining APC plasma levels.
Through their unique three-dimensional structure, aptamers
are able to selectively interact with a variety of target molecules,
ranging from proteins to peptides and small molecules. Their
binding characteristics, their production properties, and their
nontoxicity predestines them for being promising candidates
for the development of clinically useable drugs (Famulok et al.,
2007; Dollins et al., 2008). A 167 base RNA aptamer that binds
to human APC with a KD of 100 nM has been reported (Gal
et al., 1998). This aptamer inhibits the protease function of
APC, including the cleavage reaction of a fluorogenic peptide
Figure 1. Structures of the Protease
Domain of APC and In Vitro-Selected Ap-
tamers
(A) Space-filling model of the crystal structure of
APC based on the 1AUT structure deposited in
the Protein Data Bank. The side chains of basic
residues of the 39-loop, the 60-loop, and the
70–80-loop forming the basic exosite are shown
in red, whereas acidic residues of the 162 helix
are shown in blue. The catalytic triade is shown
in green in the center of the molecule.
(B) Predicted secondary structures and stabilities
(DG [kcal/mol]) of the HS02 aptamer variants.
The base numbering consistently follows that of
the full-length HS02-88 sequence.
substrate. The binding affinity of 100 nM
is rather weak when compared to that of
other aptamers that bind their corre-
sponding targets with binding affinities
in the low nanomolar or subnanomolar
ranges (Gopinath et al., 2006; Mu¨ller
et al., 2008a). Moreover, crossreactivity
of this aptamer to PC has not been tested
thus far (Gal et al., 1998). Another disad-
vantage of these molecules is their RNA
structure, which makes them sensitive
to enzymatic degradation in the plasma
or whole-blood matrix.
To overcome these drawbacks, we
selected single-stranded (ss) DNA ap-
tamers targeting recombinant APC.
Binding characteristics, the selectivity,
and the binding region were evaluated.
We demonstrate that the selected APC
aptamers specifically target the heparin-
binding site of the APC molecule, thereby
inhibiting its anticoagulant functions and
stimulating the inhibition of APC by PCI.
In turn, the aptamers are rapidly released
from the formed APC-PCI complexes.
This represents a novel mechanism of an allosteric-like, ap-
tamer-mediated protease inhibition. We conclude that the APC
aptamers represent promising candidates for the development
of clinically useable drugs specifically inhibiting APC activity
in vivo and for the development of a rapid and selective test
system that measures APC activity.
RESULTS
Aptamer Selection, Affinity, and Specificity
Prior to selection, APC was biotinylated and coupled to strepta-
vidin-coated magnetic particles, which were then used directly
during the in vitro selection (Mu¨ller et al., 2008b). As a nucleic
acid library we utilized a ssDNA pool with a 49 nucleotides
random region (Raddatz et al., 2008). After 12 selection cycles,
the enriched library was analyzed for APC binding by employing
filter retention analysis, and an increased affinity of the cycle 10
and cycle 12 ssDNA libraries compared to the starting libraryChemistry & Biology 16, 442–451, April 24, 2009 ª2009 Elsevier Ltd All rights reserved 443
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Exosite-Specific APC Targeting by DNA AptamersTable 1. Binding Affinities of the HS02 Variants to APC and Related Serine Proteases and the Zymogen Protein C
KD, nM
Aptamer rAPC pAPC pPC pFIIa rFVIIa pFIXa pFXa
HS02-88 0.43 ± 0.08 0.47 ± 0.06 155 ± 19.9 N/A N/A N/A N/A
HS02-62 0.56 ± 0.13 1.06 ± 0.23 177 ± 26.6 N/A N/A N/A N/A
HS02-52 0.35 ± 0.09 0.97 ± 0.18 181 ± 18.3 N/A N/A N/A N/A
HS02-52G 0.47 ± 0.11 0.74 ± 0.26 221 ± 46.8 N/A N/A N/A N/A
HS02-48G 0.40 ± 0.13 0.85 ± 0.06 236 ± 106 N/A N/A N/A N/A
HS02-44G 0.17 ± 0.06 0.76 ± 0.10 162 ± 60.9 N/A N/A N/A N/A
HS02-44G-CT 8.75 ± 0.96 n.d. n.d. n.d. n.d. n.d. n.d.
HS02-40 4.57 ± 1.59 n.d. n.d. n.d. n.d. n.d. n.d.
r, recombinant; p, plasma derived; N/A, not applicable (no binding observed up to 320 nM); n.d., not determined. Values are given as mean ± standard
error.was observed (data not shown) (Mu¨ller et al., 2008b). Cloning
and sequencing individual members of the DNA library corre-
sponding to the tenth selection cycle revealed a 14 base-
spanning consensus motif, 50-TATCMCGNATGGGS-30 (see
Figure S1 available online).
Among all analyzed ssDNA molecules, HS02-88 revealed the
highest affinity (KD value of 0.43 nM) and was chosen for further
characterization. Several truncated variants of the aptamer
HS02-88 were synthesized to determine the minimal sequence
requirements for high-affinity rAPC binding. The sequences
and in silico predicted secondary structures (Zuker, 2003) are
shown in Figure 1B. The binding affinities of the aptamer variants
were determined by filter retention analysis, and corresponding
KD values were calculated as described (for details, see Supple-
mental Data). As shown in Table 1, aptamer HS02-88 and the
sequentially truncated variants HS02-62, HS02-52, HS02-52G,
HS02-48G, and HS02-44G confirmed comparable binding affin-
ities in the subnanomolar to low nanomolar range. A mean Hill-
slope of 0.86 ± 0.14 as determined by a 4-parameter Hill logistic
curve fit used for the calculation of KD values indicated binding of
the aptamers to APC in a 1:1 stoichiometry.
Markedly reduced affinities of the variants HS02-44G-DCT,
lacking the CT bulge in the stem structure, and HS02-40, which
comprises a truncated stem sequence, thus leading to a destabi-
lized stem structure, were observed. These results suggest that
an overall secondary structure that bears a stem with a CT bulge
and an extended loop structure comprising the enriched 14
nucleotide consensus sequence contributes significantly to
high-affinity APC binding. To determine the specificity of the
HS02 aptamer variants, their binding activities to the proenzyme
PC, to thrombin (FIIa), and to the activated factors VII (FVIIa),
IX (FIXa), and X (FXa) were assessed by filter retention analysis.
Up to a concentration of 320 nM, neither the aptamer HS02-88
nor its truncated forms showed binding to the factors IIa, VIIa,
IXa, and Xa (Table 1). Binding to the proenzyme PC was detect-
able, but the binding affinities were 2–3 orders of magnitude
lower compared to APC. Nearly identical binding affinities were
obtained for plasma-derived APC and the recombinant version.
Influence of HS02 Aptamers on the Enzymatic
Activities of APC
Having shown that the aptamers bind with high affinity and spec-
ificity to APC, we next analyzed their influence on the amidolytic444 Chemistry & Biology 16, 442–451, April 24, 2009 ª2009 Elsevieractivity of APC. This was investigated by using a fluorogenic
peptide substrate assay. Hydrolysis rates at a final substrate
concentration of 200 mM were partially inhibited in the presence
of the full-length aptamer HS02-88 and its truncated forms,
reaching a maximum reduction of 30.51% ± 2.56%, whereas
the unselected D1 library showed no effect (Figure 2A). However,
this effect diminished when higher concentrations of substrate
were used, indicating that the aptamers alter the KM for small
peptide substrates (Figure S2).
The influence of the HS02 aptamer variants on the APC activity
toward the biological substrates FVa and FVIIIa was measured
by an FXa- and a thrombin-generation assay utilizing purified
FVIIIa and FVa, respectively. Addition of the aptamers to the
reaction mixtures resulted in a nearly complete inhibition of
APC-mediated proteolysis of FVIIIa/FVa. As shown in Table S1,
IC50 values for the inhibition of proteolysis of FVa and FVIIIa by
APC were in the low nanomolar range and were comparable
for all HS02 aptamers tested. No inhibitory effect was observed
when using increasing concentrations of the unselected D1
library.
With respect to the kinetics of cofactor inactivation shown in
Figure 2B, the aptamers significantly inhibited APC activity, as
determined by the measurement of residual FVa/FVIIIa activity
after incubation with rAPC in intervals up to 30 min. In the pres-
ence of 100 nM D1 library, the half-life times of FVa and FVIIIa in
the described test systems were determined as 3.3 and 8.3 min,
respectively. In the presence of 100 nM of the aptamer HS02-88
or its truncated variant HS02-44G, prothrombinase activity was
nearly completely preserved, yielding a mean of 86.9% ±
0.98% of initial FVa cofactor activity (Figure 2B, upper panel).
Similar results were obtained for the inhibition of APC activity
toward FVIIIa (81.4% ± 1.84% of initial tenase activity)
(Figure 2B, lower panel).
As determined by filter retention analysis, the HS02 aptamers
bind with comparable affinities to both APC and APC/Protein
S(PS) complexes (see Figure S3). To study the influence of PS
on the inhibitory capacity of the HS02 aptamers, functional
studies with purified PS have been performed. In the presence
of PS, the half-life of FVa was reduced to 0.5 min, whereas in
the presence of 100 nM HS02-88 or HS02-44G more than
50% of initial FVa cofactor activity was preserved after 30 min
of incubation (Figure 2B, upper panel, inset). These results indi-
cate that, in part, PS overcomes the inhibitory effects of theLtd All rights reserved
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Exosite-Specific APC Targeting by DNA AptamersFigure 2. The Effect of the HS02 Aptamers on the Enzymatic Activity
of APC
(A) The amidolytic activity of rAPC at a final concentration of 180 pM was
measured in the presence of HS02-88 (solid circles), HS02-62 (open circles),
HS02-52G (closed triangles), HS02-48G (open triangles), HS02-44G (closed
squares), and the unselected D1 library (open squares). Results are shown
as the mean of duplicates.
(B) The effect of the full-length HS02-88 aptamer (solid circles) and the trun-
cated HS02-44G aptamer (solid squares) on APC-mediated inactivation of
FVa and FVIIIa. Purified factors Va (upper panel) and VIIIa (lower panel) wereChemistry & Biology 16aptamers bound to APC. Because PS has been shown to accel-
erate APC-mediated cleavage of FVa at Arg506 and Arg306, no
detailed information on cleavage site(s) preferences of APC/PS
in the presence of the aptamers is available from the present
data. However, the observed high residual activity of FVa in the
absence of PS indicates that the aptamers interfere with APC-
mediated cleavage at both Arg506 and Arg306 (Norstrøm et al.,
2003).
Effect of the Aptamers on APC Anticoagulant Function
in Plasma and Whole Blood
To test the influence of the HS02 aptamer variants on the antico-
agulant function of APC in plasma and whole blood, an APC
sensitivity test was used. Because previous studies revealed
Ca2+-dependent functional activity of the aptamers in plasma
(see Figure S4), hirudin was chosen as the anticoagulant for
these experiments. Reproducible baseline- and APC-mediated
prolonged PT-clotting times were achieved at the applied
concentrations of hirudin and dilution of the used TF reagent,
allowing for reliable determination of concentration-dependent
aptamer activity.
If APC was preincubated with the aptamers before being
added to plasma, all tested aptamer variants efficiently inhibited
APC anticoagulant activity with determined IC50 values in the low
nanomolar range (mean IC50 value = 1.11 ± 0.23 nM).
As shown in Figure 3, however, addition of the aptamer
HS02-88 or the truncated variants HS02-52G, HS02-48G, and
HS02-44G to plasma or whole blood that already contained
APC revealed different functional activities of the aptamers
under this strategy. Variant HS02-52G was found to be the
most effective variant, showing IC50 values of 1.6 ± 0.1 nM and
2.7 ± 0.2 nM in the plasma and whole-blood matrix, respectively.
In contrast, the aptamer HS02-88 and its truncated variant
HS02-44G were observed to be less effective. Because the
stability of DNA aptamers in the plasma or whole-blood matrix
was found to be high (Figure S5C) (Paul et al., 2008), the
observed differences in functional activity might be traced to
the structural stability and the target specificity of the aptamers
in complex matrices.
Effect of the Aptamers on the APC-Mediated Inhibition
of Staurosporine-Induced Apoptosis
The anticoagulant and antiapoptotic functions of APC are related
to different subdomains of the protease. Therefore, we ques-
tioned whether the aptamers, which have already been shown
to inhibit the anticoagulant function of APC, possess a domain
that inhibits the anticoagulant functions of APC, but not its cyto-
protective functions, and thus show inhibitory specificity. In this
regard, the aptamer should not be able to interfere with the anti-
apoptotic function of APC. To test this hypothesis, cultured
endothelial cells of passage 4 were incubated with the ATP
analog staurosporine to induce apoptosis. Incubation with staur-
osporine resulted in an increased mean basal apoptotic rate
incubated with APC in the presence of 100 nM of the aptamers, and the
FVa/VIIIa activities were evaluated in the prothrombinase/tenase assay. The
unselected D1 library was used as control (open squares). Factor Va inactiva-
tion patterns were also assessed in the presence of 150 nM Protein S (upper
panel, inlet). All results are shown as means of duplicates., 442–451, April 24, 2009 ª2009 Elsevier Ltd All rights reserved 445
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with 20 nM APC over night (12 hr) displayed a significant reduc-
tion of the apoptosis rate reaching the baseline level. As shown in
Figure 4 and in accordance with our hypothesis, the antiapop-
totic effect of APC was influenced neither by the aptamer
HS02-88 nor by its truncated variant HS02-44G if added to the
culture medium at a final concentration of 100 nM . Experiments
with radioactively labeled HS02-88 molecules revealed that
whereas the aptamers are stable in the medium itself (Fig-
ure S5B), the concentration of aptamers dropped to 45 nM
after 8 hr and to 20 nM after overnight (14 hr) incubation on
human umbilical vein endothelial cells (HUVECs) under the given
assay conditions (Figure S5A). Nevertheless, due to the high
binding affinity of the HS02 aptamers to APC (KD of 0.5 nM),
these concentrations should have been sufficient to complex
all functional active APC molecules still remaining in the
medium.
Figure 3. The Influence of HS02 Aptamers on APC Anticoagulant
Function in Plasma and Whole Blood
(A and B) (A) Hirudin-anticoagulated plasma or (B) whole blood (B) was spiked
with rAPC, and the full-length aptamer HS02-88 (solid circles) or the truncates
HS02-52G (solid triangles), HS02-48G (open triangles), and HS02-44G (solid
squares) were added at the indicated concentrations. Clotting was initiated
by addition of tissue factor reagent. Results are shown as means of duplicates.446 Chemistry & Biology 16, 442–451, April 24, 2009 ª2009 ElsevierInfluence of the Aptamers on APC Inactivation
by the Protein C Inhibitor
Another ligand that interacts with APC is the PC inhibitor. To
study the influence of the HS02 aptamers on the formation of
APC-PCI complexes, immobilized APC was incubated with
plasma as a source of PCI. The time-dependent formation of
APC-PCI complexes was measured directly by using a PCI-
specific antibody and indirectly through hydrolysis rates of
a fluorogenic APC substrate. In the presence of 100 nM HS02
aptamers, APC inactivation rates were markedly enhanced
(Figure 5A). The loss of APC activity correlated with the formation
of APC-PCI complexes (Figure 5B). As shown in Table S2, there
was a close correlation (r = 0.95) between the size of the HS02
aptamers and the apparent first-order constants (kapp) of APC
inactivation, with the aptamer HS02-88 (kapp = 0.1221 ±
0.0158) being the most effective variant compared to the control
reaction without aptamer (kapp = 0.0232 ± 0.0045).
To study whether the HS02 aptamers dissociate from APC
after APC-PCI complexes have been formed, binding studies
with biotinylated aptamers were performed. The results shown
in Figure 5C demonstrate a decrease in the concentration of
APC-bound aptamers, while the amount of APC-PCI complexes
simultaneously increased (data not shown). In additional exper-
iments, APC was bound to immobilized HS02 aptamers and
subsequently incubated with plasma. Both PC activity and PC
Figure 4. The Influence of HS02 Aptamers on APC Antiapoptotic
Activity
Confluent monolayers of human umbilical vein endothelial cells of passage 4
were incubated overnight with 20 nM APC in the presence and absence of
100 nM HS02 aptamers. Apoptosis was induced by incubation with stauro-
sporine at 2 mM for 4 hr. Then, the cells were fixed with 4% paraformaldehyde,
and apoptotic nuclei were stained with the TUNEL reaction mixture. Results
are shown as means with standard deviations of three independent experi-
ments. *p < 0.01 (ANOVA).Ltd All rights reserved
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(A) Immobilized APC was incubated with plasma, and the time-dependent
changes in APC activity were measured through hydrolysis rates of a fluoro-
genic APC substrate.
(B) Formed APC-PCI complexes were measured in an ELISA format utilizing
a POD-labeled goat anti-human PCI antibody without aptamers (solid dia-
monds), 100 nM of unselected D1-library (open squares), HS02-88 (solidChemistry & Biology 16antigen levels decreased over time, indicating that the formed
APC-PCI complexes dissociate from the immobilized aptamers
(Figure S6). Furthermore, no binding of plasma PCI could be de-
tected in the wells.
Heparin Competition Experiments
Heparin has been shown to bind to the basic exosite of APC
(Friedrich et al., 2001). To study whether the binding site of the
HS02 aptamers is identical or overlaps with the binding region,
competition experiments were performed. Increasing concen-
trations of unfractionated heparin (UFH) inhibited the binding of
radioactively labeled aptamers to APC with a mean IC50 value
of 6.73 ± 1.72 mM. The calculated mean Hill-slope of 1.07 ±
0.22 indicates that UFH and the aptamers competed for the
same binding site on the APC molecules (Figure 6).
Influence of the Aptamers on PC Activation
by Thrombin/Thrombomodulin
To study if the aptamers have an effect on PC activation by
thrombin/thrombomodulin, an amidolytic APC-generation assay
was used. As shown in Figure S7, aptamers HS02-88, HS02-
52G, and HS02-44G interfered with APC generation in a size-
and concentration-dependent manner. In accordance with the
determined PC-binding affinities of the aptamers, however, this
effect only became distinct at aptamer concentrationsR200 nM.
DISCUSSION
We identified a novel, to our knowledge, class of high-affinity
ssDNA ligands that selectively bind to human APC. Based on
secondary structure analysis and the evaluation of truncated ap-
tamers, a stem loop structure together with a CT bulge were
found to represent a critical structural motif for high-affinity
APC binding.
APC belongs to the group of vitamin K-dependent clotting
factors that are characterized by the presence of a g-carboxy-
glutamic acid domain at the amino end of the protein and
show a high degree of structural homology (Stenflo, 1999). Filter
retention analysis with activated forms of factors II, VII, IX, and X
ruled out any significant binding of the APC aptamers to these
structurally related proteases, thus emphasizing the high degree
of specificity of the selected aptamer and its truncated variants.
The vitamin K-dependent clotting factors circulate in the blood
stream in their zymogen variant until the coagulation pathway
becomes activated. Aptamers to a variety of vitamin K-depen-
dent clotting factors that bind their corresponding targets with
KD values ranging fromz0.5 nM to 50 nM have been generated.
Despite the fact that these aptamers were selected against the
active enzyme, they bind the corresponding zymogens with
circles), HS02-62 (open circles), HS02-52G (solid triangles), HS02-48G
(open triangles), and HS02-44G (solid squares).
(C) Release of HS02 aptamers upon APC-PCI complex formation. 30-biotiny-
lated variants of HS02-88 (circles) and HS02-44G (squares -) were bound
to immobilized APC prior to the addition of plasma or buffer. As determined
by POD-labeled streptavidin, incubation with buffer (gray symbols) did not
lead to a detectable release of aptamers over time. In contrast, addition of
plasma initiated APC-PCI complex formation (data not shown) and a corre-
sponding loss of streptavidin-mediated detection of aptamers (black
symbols). Results are shown as means of duplicates., 442–451, April 24, 2009 ª2009 Elsevier Ltd All rights reserved 447
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coni et al., 2000; Gopinath et al., 2006). The binding affinities of
the HS02 aptamer variants regarding PC were found to be
200 times weaker than that observed for APC binding. This
remarkable specificity renders the HS02 aptamer variants prom-
ising candidates for the development of rapid APC-specific
assays, because the development of such an assay requires
ligands with the ability to distinguish between PC and APC
because the plasma level of PC is estimated to be 1000-fold
greater than the concentration of APC. At present, only one
monoclonal antibody (HAPC 1555) has been identified that
shows a 10-fold higher affinity toward APC than to PC (Esmon
et al., 2002).
To map the binding site of HS02 to APC, we performed a series
of functional studies and competition experiments with known
APC ligands. The amidolytic activity of APC is only partially influ-
enced by HS02, indicating that the catalytic apparatus of APC is
not directly blocked by HS02, but makes a binding region in
close contact to the active site most likely. The active site cleft
is flanked by two exosites that are involved in the interaction of
APC with its macromolecular substrates. According to chymo-
trypsin numbering, one of these exosites, the basic exosite,
comprises the 37-loop (Lys37–Lys39), the 60-loop (Lys62 and
Lys63), and the 70–80-loop (Arg74, Arg75, and Lys78) of APC (Frie-
drich et al., 2001; Yang et al., 2002). The mutagenesis of basic
residues of the 37-loop and the 70–80-loop has resulted in
mutant proteases with markedly impaired anticoagulant activity,
indicating that the basic exosite is involved in interaction of APC
with factors Va and VIIIa (Friedrich et al., 2001; Yang et al., 2002;
Gale et al., 2002; Manithody et al., 2003). The dose-dependent
inhibition of APC-mediated cleavage of factors Va and VIIIa by
HS02 suggests that the aptamers inhibit binding of FVa/FVIIIa
to APC, most likely through blockade of the basic exosite.
Another ligand that binds to APC through the basic exosite is
heparin (Friedrich et al., 2001). Heparin competitively inhibits
binding of HS02 aptamers to APC. Thus, these data provide
Figure 6. Heparin Competition Experiments
Radioactively labeled aptamers HS02-88 (closed
circles), HS02-62 (open circles), HS02-52G
(closed triangles), HS02-48G (open triangles),
and HS02-44G (closed squares) were incubated
with APC in the presence of increasing concentra-
tions of UFH. Filter retention analysis indicated
competitive inhibition of aptamer binding by UFH
(mean Hill-slope =1.07 ± 0.22; mean IC50 value =
6.73 ± 1.72 mM). Results are shown as means of
duplicates.
further evidence that the basic exosite is
indeed the binding site of the HS02 ap-
tamer variants.
Heparin binding to APC has been
shown to accelerate the PCI-mediated
inhibition of APC in a molecular weight-
dependent manner (Aznar et al., 1996).
It is anticipated that heparin induces the
formation of a ternary complex between
heparin, APC, and PCI, and that inhibition
of APC by PCI works by a template mechanism wherein APC and
PCI bind to the same heparin molecule (Li and Huntington, 2008).
To study whether aptamer binding interferes with PCI-mediated
inactivation of APC, we performed a series of APC inhibition
experiments. The HS02 aptamers accelerate the inactivation
kinetics of APC by PCI in a concentration- and size-dependent
manner. However,afterAPC-PCIcomplex formation, theaptamers
were shown to be rapidly released, revealing a novel aptamer-
based inhibitory mechanism. These observations might indicate
that the aptamer-binding epitope of APC is not directly involved
in the complex formation between APC and PCI, but that the
conformational changes induced by APC-PCI complex formation
alters this epitope in a way that consequently leads to the release
of the aptamer. In contrast to heparin, the aptamers did not show
any binding to PCI or APC-PCI complexes, making it most unlikely
that they are directly involved in the formation of a ternary complex
through a template mechanism. Thus, allosteric changes within the
APC molecule upon aptamer binding might account for the
observed effects. Interestingly, a comparable mechanism has
been reported previously for an RNA aptamer that binds the
anion-binding exosite 2 of thrombin (Jeter et al., 2004). Taken
together, these resultsmake theHS02 aptamers interesting molec-
ular tools for studies on the interaction between APC and PCI.
A second exosite is located within the APC molecule opposite
to the basic exosite on the left of the active site toward the back
of the molecule and is formed by acidic residues of the 162 helix.
This acidic exosite determines the specificity of the protease
interaction with PAR-1 and thereby determines its cytoprotective
properties (Yang et al., 2007). To test, if the cytoprotective func-
tions of APC are influenced by aptamer binding, we performed
a staurosporine-induced apoptosis assay with HUVECs. This is
an established model system by which to study antiapoptotic
effects of APC (Isermann et al., 2007; Bae et al., 2007). Whereas
APC significantly reduced the staurosporine-induced apoptosis
rates, none of the HS02 aptamers inhibit this cytoprotective
effect of APC. These results support previous findings obtained448 Chemistry & Biology 16, 442–451, April 24, 2009 ª2009 Elsevier Ltd All rights reserved
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in the cytoprotective functions of APC and gave additional
evidence that the binding site of the HS02 aptamers is located
in the basic exosite of APC (Bae et al., 2007; Mosnier et al., 2004).
Although effective in the treatment of severe sepsis, adminis-
tration of rAPC is complicated by the occurrence of major and
life-threatening bleeding complications in 2% of patients (Levi,
2008; Vincent et al., 2005). These bleeding complications are
induced by the anticoagulant functions of APC, whereas several
in vitro and in vivo data indicate that the therapeutic efficacy of
APC in severe sepsis is mainly due to APC’s cytoprotective
effects (Toltl et al., 2008). It is therefore tempting to speculate
that the ability to selectively inhibit APC’s anticoagulant activity
makes the aptamers promising therapeutic agents to be used
for the treatment of APC-induced bleeding complications.
Other interactions of APC with macromolecular substrates
involve binding of APC to its cofactor PS. Using the newly char-
acterized aptamers, we were able to show that the basic exosite
is not involved in binding of APC to PS. These data extend and
confirm recently published data showing that PS primarily binds
to the GLA domain region of APC (Harmon et al., 2008).
In summary, we have identified and characterized ssDNA ap-
tamers that bind with high affinity to the basic exosite of APC.
Through blockade of this exosite, the APC aptamers act as selec-
tive and potent inhibitors of APC’s anticoagulant functions. Simul-
taneously, binding of HS02 to APC enhanced inactivation rates of
the protease by the serpin PCI. The antiapoptotic effect of APC is
not inhibited by the APC aptamers, indicating that the cytoprotec-
tiveeffectsofAPCremain intactafteraptamerbinding.Theaptamer
represents an excellent starting point for the development of selec-
tive and sensitive diagnostic formats and APC-modulating drugs.
SIGNIFICANCE
APC controls the clotting process by downregulation of
thrombin formation and possesses anti-inflammatory and
cytoprotective functions. Given these important physiolog-
ical functions of APC, determination of plasma levels of
this protease are of clinical interest in the characterization
of a hypercoagulable state and/or an inflammatory state.
Specific detection and quantification of APC are hampered
by the fact that a highly selective ligand that discriminates
between APC and its precursor PC is not available. To
circumvent this limitation, we used the aptamer technology
to select a class of high-affinity (KD ofz0.5 nM) ssDNA APC
aptamers, designated HS02. Binding to the zymogen PCwas
200-fold weaker, making the HS02 aptamers promising
ligands for the development of APC-specific assays. APC-
related bleeding complications are a relevant problem in
patients receiving recombinant APC for the treatment of
severe sepsis. The HS02 aptamers inhibit the anticoagulant
functions of APC by binding to the basic exosite of APC, but
not the antiapoptotic and cytoprotective functions of the
enzyme. The ability to selectively inhibit APC’s anticoagulant
functions makes HS02 a potential therapeutic agent for the
treatment of APC-related bleeding. Finally, the exosite spec-
ificity of the APC aptamer makes it an interesting molecular
tool by which to probe APC’s interactions with several
macromolecular substrates and cellular receptors.Chemistry & Biology 16EXPERIMENTAL PROCEDURES
Proteins, Reagents, and Oligonucleotide Library
A recombinant version of human APC (rAPC, Xigris) was purchased from Eli
Lilly (Indianapolis, USA), and recombinant human Factor VIIa (NovoSeven)
was purchased from Novo Nordisk (Bagsværd, Denmark). The plasma-derived
human PC concentrate (Ceprotin) and recombinant FVIII (Recombinate) were
purchased from Baxter (Unterschleißheim, Germany). Ceprotin was activated
to APC by using human a-thrombin (for details, see Supplemental Data). All
other coagulation enzymes were purchased from CellSystems (St. Katharinen,
Germany) unless otherwise stated. Argatroban was obtained from Mitsubishi
Pharma (Du¨sseldorf, Germany). Unfractionated heparin (UFH, Liquemin), the
TUNEL assay kit, POD-labeled streptavidin, and the BM chemiluminescence
substrate were obtained from Roche (Mannheim, Germany). Endothelial cell
basal medium (ECBM) and FCS were purchased from Promocell (Heidelberg,
Germany). The fluorogenic substrates PCa 3342 (Pyr-CHG-Arg-AMC) and
PCa 5791 (Pyr-Pro-Arg-AMC) were purchased from Loxo (Dossenheim,
Germany), and the rabbit anti-human PC antibodies and POD-labeled goat
anti-rabbit antibodies were obtained from Dako (Glostrup, Denmark). The
POD-conjugated goat anti-human PCI antibody was purchased from Haemo-
chrom Diagnostica (Essen, Germany). Rabbit thrombomodulin was purchased
from American Diagnostica (Pfungstadt, Germany). Streptavidin was
purchased from Applichem (Darmstadt, Germany). The fluorogenic substrates
Z-Gly-Gly-Arg-AMC and Boc-Ile-Glu-Gly-Arg-AMC were purchased from
Bachem (Weil am Rhein, Germany). The EZ-link biotin hydrazide (NHS-Biotin)
was purchased from Perbio Science (Bonn, Germany). The tissue factor
reagent Innovin and the aPTT reagent Actin FS and soybean phospholipids
were purchased from Siemens Healthcare Diagnostics (former Dade Behring,
Marburg, Germany). For the preparation of a stock solution, dried soybean
phospholipids were dispersed in water by using a water bath sonicator to
obtain a final concentration of 1 mg/ml (1.3 mM). Streptavidin-coated magnetic
beads (Dynabeads M-280 Streptavidin) were purchased from Invitrogen
(Karlsruhe, Germany).
An HPLC-purified ssDNA library (D1) that contained a randomized sequence
of 49 nucleotides flanked by 2 primer hybridization sites (50-GCCTG
TTGTGAGCCTCCTAAC-N49-CATGCTTATTCTTGTCTCCC-3
0) was obtained
from Metabion (Martinsried, Germany) and used as the primary library for the
SELEX procedure. The corresponding amplification primers were purchased
from Operon (Cologne, Germany).
SELEX
To enable the removal of unbound ssDNA molecules during the SELEX
process, rAPC was coupled to magnetic beads for separation. First,
1.82 mmol (100 mg) reconstituted rAPC was incubated with 5.46 mmol NHS-
Biotin in a total volume of 100 ml for 30 min on ice, followed by a 10 min incu-
bation at room temperature. To remove unbound NHS-Biotin, the reaction
mixture was applied to a Micro Bio Spin 6 chromatography column according
to the manufacturer’s instructions (Biorad, Munich, Germany). Purified rAPC-
Biotin (100 mg) was added to 500 ml binding buffer (13 PBS [pH 7.4], 1 mg/ml
BSA) containing 5 mg streptavidin-coated magnetic beads and incubated at
room temperature for 30 min under constant agitation. After incubation,
primed beads (rAPC beads) were washed and stored in 1 ml binding buffer
at 4C until used. The SELEX procedure was started by incubation of
500 pmol D1 library with 400 mg rAPC beads in a total volume of 160 ml selec-
tion buffer (PBS [pH 7.4], 1 mM each CaCl2 and MgCl2, 1 mg/ml BSA) for
30 min at 37C. After washing with selection buffer, rAPC-bound aptamers
were eluted by incubation in 55 ml water at 80C for 3 min and reamplified
with primers 50-GCCTGTTGTGAGCCTCCTAAC-30 (D1F, forward) and 50-GGG
AGACAAGAATAAGCATG-30 (D1RB, reverse). Reverse primers were biotiny-
lated at the 50 end to enable the removal of reverse complement sequences
by using streptavidin-coated magnetic beads as previously described (Rad-
datz et al., 2008). After denaturation of the double-stranded PCR products,
50 pmol isolated sense strands was introduced to the subsequent rounds of
SELEX. From the third round, selected aptamers were preincubated with
400 mg nonloaded streptavidin-coated magnetic beads in order to eliminate
potentially present sequences binding to streptavidin or bead structures.
Twelve iterations of SELEX were performed. Due to the increasing amount
of target-binding aptamers, the number of PCR cycles was reduced from, 442–451, April 24, 2009 ª2009 Elsevier Ltd All rights reserved 449
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gency of the selection process, the number of performed washing cycles was
doubled after each round, starting from 1 to a maximum of 8 (rounds 4–12). The
selection process was monitored by dHPLC analysis as previously described
(Mu¨ller et al., 2008b). Detailed information on cloning of selected aptamers,
sequence analysis, and the synthesis of candidate aptamers and controls is
given in Supplemental Data.
Catalytic Activity of APC against Small Substrates
To assess the influence of aptamer binding on the amidolytic activity of APC,
50 ml 360 pM (20 ng/ml) rAPC in selection buffer containing different concen-
trations of aptamers or controls (0–360 nM) was placed into wells of white F8
Fluoronunc modules (Thermo Fisher Scientific, Nunc, Wiesbaden, Germany).
Subsequently, 50 ml 400 mM Pyr-CHG-Arg-AMC (Pefa 3342) was added and
substrate hydrolysis was monitored at 30C by using an automated plate fluo-
rescence/luminescence reader (Ascent Fluoroscan, Thermo Fisher Scientific,
Dreieich, Germany). Alternatively, APC-amidolytic activity was determined in
the absence or presence of 100 nM aptamers HS02-88 or HS02-44G and
0.01–2.5 mM Pefa 3342 (final concentrations).
Anticoagulant Activity of APC
The influence of aptamer binding on the anticoagulant activity of APC was
measured by using a prothrombin-time (PT)-based one-stage clotting assay.
Two different strategies were applied. First, 3.6 nM (200 ng/ml) APC was pre-
incubated with 0–250 nM of the aptamers in TBS buffer (10 mM Tris-HCl
[pH 7.4], 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 1 mg/ml BSA). Subse-
quently, 20 ml of this solution was added to 30 ml hirudin-anticoagulated
plasma (10 mg/ml hirudin) and incubated for 2 min at 37C. To start the clotting
reaction, 60 ml tissue factor reagent (Innovin, 1:2 diluted in TBS) was added.
Second, 30 ml hirudin-anticoagulated whole blood (5 mg/ml hirudin) or the
corresponding plasma was spiked with 10 ml rAPC in TBS buffer (10 mM
Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 1 mg/ml BSA)
to achieve final concentrations of 2.6 nM (140 ng/ml) or 550 pM (30 ng/ml),
respectively. Subsequently, 10 ml aptamers (0–500 nM) in TBS buffer was
added. After incubation for 3 min at 37C, coagulation was initiated by the
addition of 60 ml tissue factor reagent (Innovin, 1:2 diluted in TBS). All measure-
ments were automatically performed by using the coagulation analyzer AMAX
CS 190 (Amelung, Lemgo, Germany).
Monitoring of FVa/FVIIIa Inactivation by APC
APC-mediated inactivation of FVIIIa and FVa was monitored in a purified
system by using an FXa-generation assay and a thrombin-generation assay,
respectively. Both assays were performed in 96-well microtiter plates.
Activated FVIII used for the FXa-generation assay was prepared by incuba-
tion of 1 U recombinant human FVIII (Recombinate) with 0.025 U human
a-thrombin in PBS buffer ([pH 7.4] 1 mg/ml BSA) in a total volume of 100 ml.
After 2 min of incubation at room temperature, 5 ml 1.4 nM hirudin was added
to terminate thrombin activity. Activated FVIII at a concentration of 0.16 U/ml
was incubated with 1.8 nM rAPC in assay buffer (20 mM Tris-HCl [pH 7.6],
137 nM NaCl, 10 mg/ml phospholipids, 5 mM CaCl2, 1 mg/ml BSA) in the
absence or presence of aptamers or controls (0.06–180 nM). After incubation
for up to 30 min, 25 ml of the mixtures was transferred to the wells of black F16
Fluoronunc modules (Thermo Fisher Scientific, Nunc) containing 3 nM human
FIXa and 333 mM Boc-Ile-Glu-Gly-Arg-AMC in a total volume of 75 ml assay
buffer. Subsequently, 50 ml 25 nM human FX in assay buffer was added to
the wells and the kinetics of FXa-mediated substrate hydrolysis monitored at
30C by using an automated plate fluorescence reader (FLx-800, Bio-Tek,
Bad Friedrichshall, Germany).
For determination of FVa inactivation, 625 pM FVa was incubated at room
temperature with 18 pM rAPC in the absence or presence of 150 nM PS in
assay buffer containing different concentrations of aptamers or controls
(0–180 nM). After incubation for up to 30 min, 25 ml of the mixtures was trans-
ferred to the wells of white F8 Fluoronunc modules (Thermo Fisher Scientific,
Nunc) containing 42 pM human FXa and 667 mM fluorogenic peptide substrate
Z-Gly-Gly-Arg-AMC in a total volume of 75 ml in assay buffer. Subsequently,
50 ml 25 nM human prothrombin in assay buffer was added, and the kinetics
of thrombin-mediated substrate hydrolysis was monitored by using the Ascent
reader.450 Chemistry & Biology 16, 442–451, April 24, 2009 ª2009 ElsevierResidual cofactor activities were calculated according to a parallel-pro-
cessed dilution series of FVa or FVIIIa in the absence of APC and aptamers
during the first incubation step.
Staurosporine-Apoptosis Assay
Human umbilical vein endothelial cells (HUVECs) were used for this experiment.
Aptamers (HS02-88, HS02-44G and the scrambled control sequence) were pre-
incubated with APC in selection buffer for 5 min at 37C. HUVECs of passage 4
grown to confluency were pretreated with 20 nM APC alone as well as with
20 nM APC along with 100 nM aptamers in ECBM (0.5% FCS) overnight
(12 hr). Then, the cells were incubated with 2 mM staurosporine (Sigma-
Aldrich, Germany) for 4 hr to induce apoptosis. Cells were fixed with 4% para-
formaldehyde, and apoptotic nuclei were stained by using the TUNEL assay kit.
Stability of the HS02 Aptamers on HUVECs and in Whole Blood
To assess the extracellular half-life of the aptamers in the presence of HUVECs as
well as their stability in the used ECBM, 1% of radioactively labeled HS02-88
molecules were introduced together with unlabelled molecules at a final concen-
tration of 100 nM to the culture medium and either incubated overnight on
confluent HUVECs or in medium alone. For determination of aptamer stability in
whole blood, the same mixture of aptamers was added to hirudin-anticoagulated
whole blood (100 nM final concentration) and incubated at 37C for up to 2 hr.
Generally, samples were taken at different time points, and aptamers were iso-
lated by phenol-chloroform extraction from medium or plasma, assessed for
quantity and structural integrity on 8% PAGE gels with the radioactivity exposed
on storage phosphor screens, and subsequently analyzed as described above.
Monitoring of APC Inactivation by PCI and Release of Aptamers
from APC-PCI Complexes
Inactivation rates of immobilized APC by PCI were studied in the absence and
presence of aptamers by using combined immunological and functional
assays. Human plasma was used as a PCI source. The assays were performed
in the microtiter plate format (for details, see Supplemental Data).
APC-Generation Assay
Formation of APC by thrombin/thrombomodulin complexes was monitored by
using a fluorogenic assay as previously described (Mu¨ller et al., 2008a), with
slight modifications. A detailed description of the performed assay is given
in the Supplemental Data.
Data Analysis
All experiments were performed in duplicate, and data are shown as mean
values. Sequence alignments were done by using the ClustalW tool available
on the EMBI-EBI homepage (http://www.ebi.ac.uk/clustalW). Secondary
structure analysis of aptamer sequences was done by using the Mfold web
server for nucleic acid folding available at http://mfold.bioinfo.rpi.edu/
cgi-bin/dna-form1.cgi (Zuker, 2003). Dissociation constants (KD) and IC50
values were calculated by a 4-parameter Hill logistic curve fit. Inhibition, loss
of binding, and complex formation data were interpolated by a 3-parameter
exponential curve fit. Apparent first-order constants (kapp) of APC inactivation
were determined by an exponential curve fit according to x = x0*e
kapp*t,
where x is the residual amidolytic rAPC activity at time point t (0–10 min) and
x0 is the fitted amidolytic APC activity in the buffer control. All calculations
were done by using SigmaPlot 9.0 or Excel 2003 software.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, seven
figures, and two tables and can be found with this article online at http://
www.cell.com/chemistry-biology/supplemental/S1074-5521(09)00110-0.
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